Oral osteoporosis meds appear to reduce the risk of jaw degradationJanuary 03, 2008Athanasios Zavras began receiving messages from distraught patients in 2005 after case reports linked oral osteoporosis meds to bone death in the jaw. A number of doctors and dentists advised women and men taking these drugs to postpone dental work, fearing that procedures such as tooth extractions would exacerbate the problem. That's when Zavras, an associate professor in the Harvard School of Dental Medicine, decided to take a closer look at the purported link. After analyzing the medical claims of 714,217 people, Zavras, along with Vassiliki Cartsos at the Tufts University School of Dental Medicine and Shao Zhu of Ingenix-i3 Drug Safety (the company that provided medical claims data), have concluded that oral osteoporosis meds seem to reduce the risk of jaw degradation. Clinical studies are needed to replicate and clarify the results, which appear in the January issue of the Journal of the American Dental Association. "This is good news for the roughly 3 million Americans who take Fosamax, Actonel, Boniva or similar osteoporosis meds orally," says Zavras, who is also director of dental public health in the Department of Oral Health Policy and Epidemiology. The drugs, which are called bisphosphonates, inhibit cells that break down bone tissue, and a growing number of Americans with osteoporosis or low bone mass ingest them orally to halt bone loss. In fact, they have been used for this purpose since 1977. Some cancer patients also rely on bisphosphonates to prevent bone fragility and metastasis, but these individuals typically receive potent intravenous versions of the drugs. In 2003, case reports linked the potent versions to bone death in the jaw, and subsequent studies confirmed the statistical significance of the association. Concern was limited to intravenous bisphosphonates until May 2005, when the Journal of Oral and Maxillofacial Surgery published a report on 63 patients with bone death in the jaw. Seven of those patients had taken oral bisphosphonates. Zavras and his colleagues used a medical claims database from a large national health insurance plan to probe the connection. They analyzed records coded under osteoporosis, female breast cancer, lung cancer, prostate cancer or multiple myeloma from April 2000 through April 2006, which gave them a pool of 714,217 people. Based on pharmacy and drug infusion claims, the researchers were able to determine if these individuals had received oral bisphosphonates, intravenous bisphosphonates, or neither. Next, the team examined claims for adverse bone outcomes and major surgery in the oral cavity to determine which patients might have experienced "jaw death." Osteoporosis patients who took oral bisphosphonates were slightly less likely to have adverse jaw outcomes than osteoporosis patients who were not taking the drugs. The protective association was statistically significant. A generally similar pattern emerged in the analysis of people with cancer. Those who had received oral bisphosphonates experienced protective associations or slightly increased risks that were not statistically significant. But receiving intravenous bisphosphonates significantly increased an individual's risk for adverse jaw outcomes in both cancer patients and those with osteoporosis. "Our findings on intravenous bisphosphonates are consistent with the literature, which makes me confident that our findings on oral bisphosphonates are correct," says Zavras. "We're currently recruiting patients for a clinical study to confirm them." Harvard Medical School |
|||||||||||||||||||||
| Related Bisphosphonates Current Events and Bisphosphonates News Articles Space-related radiation research could help reduce fractures in cancer survivors A research project looking for ways to reduce bone loss in astronauts may yield methods of improving the bone health of cancer patients undergoing radiation treatment. Buyer beware: Estrogen supplements not as effective as claimed Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University. Denosumab increases bone density, cuts fracture risk in prostate cancer survivors Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. Monitoring bone density in older women is unnecessary and potentially misleading Monitoring bone mineral density in postmenopausal women taking osteoporosis drugs (bisphosphonates) is unnecessary and potentially misleading. A stronger backbone: DHEA hormone replacement increases bone density in older women Taking a DHEA supplement combined with vitamin D and calcium can significantly improve spinal bone density in older women, according to a new study from a Saint Louis University scientist and his colleagues at Washington University. X-rays help predict permanent bone damage from bisphosphonates Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. Link between widely used osteoporosis drugs and heart problems probed New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat. New drug agent knocks out multiple enzymes in cancer pathway A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials. Heart failure patients have higher risk of fractures Heart failure patients are at higher risk for fractures, including debilitating hip fractures, than other heart patients and should be screened and treated for osteoporosis, Canadian researchers reported in Circulation: Journal of the American Heart Association. Bone drug could help prevent the spread of breast cancer Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis. More Bisphosphonates Current Events and Bisphosphonates News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||